BMY Earnings Prediction
The chart below shows how BMY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BMY sees a +0.17% change in stock price 10 days leading up to the earnings, and a +0.27% change 10 days following the report. On the earnings day itself, the stock moves by -0.43%. This data can give you a slight idea of what to expect for the next quarter's release.
BMY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
12.34B
7.54%
3.78%
Gross Margin
60.26%
6.52%
8.09%
Operating Margin
24.57%
8.00%
5.68%
Net Margin
0.62%
-95.96%
-93.93%
EPS
0.04
-95.40%
-93.33%
No Data Available
BMY Earnings Analysis
Bristol-Myers Squibb Co Corporation (BMY.N) Earnings Conference Call
Positive
Fourth Quarter Sales Growth: Sales in the fourth quarter grew 9% to approximately $12.3 billion, driven by volume growth across the portfolio and higher inventory levels in the market.
Strong Sales Growth: The growth portfolio delivered another strong quarter with sales up 23%, representing slightly more than half of total revenue, with key brands like REBIZEL, Briyansi, Khemzias, and Optilag achieving significant growth.
Eliquis Q4 Sales Surge: Eliquis delivered over $3 billion in fourth quarter sales, with U.S. sales growing 19% due to strong demand and typical inventory build.
Strong Sales Uptake: Cobenphi sales in the fourth quarter were approximately $10 million, reflecting strong prescription uptake during the initial months of launch, with favorable feedback from patients and physicians.
Cost Savings Expansion: The company expects to capture an additional $2 billion in savings from an expanded cost savings program, with approximately $1 billion to be realized in 2025, enhancing financial flexibility for growth investments.
Negative
Revenue Guidance Adjustment: Revenue guidance for 2025 is approximately $1,000,000,000 less than consensus, primarily due to expected declines in the legacy portfolio, with a projected 18% to 20% decline due to generics and foreign exchange headwinds.
Legacy Portfolio Decline: The legacy portfolio is expected to decline approximately 10% to 12% sequentially in 2025, reflecting the impact of increased generic competition and the anticipated loss of exclusivity for key products like Revlimid and POMALYST.
Gross Margin Decline: Gross margin declined by approximately 240 basis points in the fourth quarter, driven primarily by product mix, indicating potential pressure on profitability moving forward.
Rising Operating Expenses: Operating expenses increased approximately 8% in the fourth quarter, largely driven by R&D investments, which may limit the company's ability to manage costs effectively in the near term.
Effective Tax Rate Increase: The effective tax rate for the quarter was 19.9%, up from 14.9% in the prior year, primarily driven by earnings mix, which could impact net income and earnings per share going forward.
BMY FAQs
How does BMY typically perform around its earnings report dates?
Is Bristol-Myers Squibb Co (BMY) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BMY Earning Call Sentiment
Earnings call transcript: Bristol-Myers Squibb Q4 2024 beats estimates
BMY.N
2.47%Positive
The earnings call indicates mixed signals. Strong financial performance and optimistic guidance are countered by concerns about supply chain challenges, economic factors, and regulatory impacts. The Q&A session reveals some uncertainty, particularly around cost management and regulatory impacts. While growth prospects and cost savings are positive, the lack of clarity on certain issues tempers the overall sentiment, resulting in a neutral outlook.
